BIO-Europe Spring 2019: Virion CEO Outlines Plans For The First Broad-Spectrum Respiratory Antiviral
Executive Summary
Today, the vast majority of respiratory viruses are not addressable with either vaccines or treatments. Virion Biotherapeutics is aiming to change that, using scientific knowledge developed at the University of Warwick. CEO Vanessa King spoke to Scrip at BIO-Europe Spring 2019.